英文名稱 | Sofosbuvir | PSI-7977 | GS-7977 |
---|---|
中文名稱 | 索非布韋 | 索氟布韋 |
CAS號 | 1190307-88-0 |
分子式 | C22H29FN3O9P |
分子量 | 529.45 |
外觀 | White to off-white powder |
儲存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
英文名稱 | Sofosbuvir | PSI-7977 | GS-7977 |
---|---|
中文名稱 | 索非布韋 | 索氟布韋 |
CAS號 | 1190307-88-0 |
分子式 | C22H29FN3O9P |
分子量 | 529.45 |
外觀 | White to off-white powder |
儲存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Sofosbuvir (also known as PSI-7977, GS-7977; PSI7977; GS7977; Vosevi; Hepcinat; Hepcvir; Resof; Sovaldi and Virunon), ablockbuster anti-HCV drug, is an HCV NS5B polymerase inhibitor that has been approved for the treatment of chronic hepatitis C virus (HCV) infections.
Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.
J Biol Chem. 2010 Nov 5;285(45):34337-47.
PMID: 20845908 DOI: 10.1021/jm100863x
Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.
PMID: 22430955 PMCID: PMC3370800 DOI: 10.1128/AAC.00054-12